0.7146
price down icon3.17%   -0.0234
pre-market  プレマーケット:  .73   0.0154   +2.16%
loading
前日終値:
$0.738
開ける:
$0.734
24時間の取引高:
710.61K
Relative Volume:
0.81
時価総額:
$31.19M
収益:
-
当期純損益:
$-31.11M
株価収益率:
-0.4671
EPS:
-1.53
ネットキャッシュフロー:
$-28.18M
1週間 パフォーマンス:
-13.20%
1か月 パフォーマンス:
-11.71%
6か月 パフォーマンス:
-46.27%
1年 パフォーマンス:
-86.86%
1日の値動き範囲:
Value
$0.7045
$0.75
1週間の範囲:
Value
$0.7045
$0.84
52週間の値動き範囲:
Value
$0.6986
$6.00

Tempest Therapeutics Inc Stock (TPST) Company Profile

Name
名前
Tempest Therapeutics Inc
Name
セクター
Healthcare (1165)
Name
電話
415-798-8589
Name
住所
2000 SIERRA POINT PARKWAY, BRISBANE
Name
職員
17
Name
Twitter
Name
次回の収益日
2025-03-26
Name
最新のSEC提出書
Name
TPST's Discussions on Twitter

TPST を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
TPST
Tempest Therapeutics Inc
0.7146 31.19M 0 -31.11M -28.18M -1.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.74 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
617.00 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
567.09 34.59B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
255.76 33.10B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
271.04 29.15B 3.81B -644.79M -669.77M -6.24

Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-03-14 開始されました Scotiabank Sector Outperform
2024-02-08 開始されました Jefferies Buy

Tempest Therapeutics Inc (TPST) 最新ニュース

pulisher
Mar 31, 2025

FY2028 Earnings Estimate for TPST Issued By William Blair - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

What is HC Wainwright’s Estimate for TPST Q1 Earnings? - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

Scotiabank Has Lowered Expectations for Tempest Therapeutics (NASDAQ:TPST) Stock Price - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Scotiabank Lowers Tempest Therapeutics (NASDAQ:TPST) Price Target to $7.00 - Armenian Reporter

Mar 30, 2025
pulisher
Mar 30, 2025

HC Wainwright Has Lowered Expectations for Tempest Therapeutics (NASDAQ:TPST) Stock Price - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Tempest Therapeutics Advances Cancer Therapies Amid Financial Challenges - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

H.C. Wainwright cuts Tempest Therapeutics stock target to $16 By Investing.com - Investing.com UK

Mar 28, 2025
pulisher
Mar 27, 2025

Tempest Therapeutics Inc. (TPST) reports earnings - Quartz

Mar 27, 2025
pulisher
Mar 27, 2025

Why Super Micro Computer Stock Was Sliding This Week - The Globe and Mail

Mar 27, 2025
pulisher
Mar 27, 2025

Tempest Reports Year End 2024 Financial Results and Provides Business Update - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Tempest's Cancer Drug Shows 6-Month Survival Gain, Lands Major Roche Partnership - Stock Titan

Mar 27, 2025
pulisher
Mar 26, 2025

Tempest Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView

Mar 26, 2025
pulisher
Mar 25, 2025

Tempest Announces Amezalpat Poster Presentation at the 2025 - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Breakthrough Cancer Drug Data Reveals New Immune Response Findings at AACR 2025 - Stock Titan

Mar 25, 2025
pulisher
Mar 13, 2025

Tempest Therapeutics advances Phase 2 trial for cancer prevention By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

FDA Study May Proceed Notice Received for Phase 2 Trial of - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Tempest Therapeutics Says Familial Adenomatous Polyposis Trial Gets US FDA 'Study May Proceed' Notice - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Tempest Therapeutics advances Phase 2 trial for cancer prevention - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Tempest gets FDA nod to begin mid-stage study of its therapy for colon cancer-causing genertic condition - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

FDA Green Light: Tempest's Revolutionary FAP Drug Advances to Phase 2 with NCI Backing - StockTitan

Mar 13, 2025
pulisher
Mar 11, 2025

Tempest Therapeutics (TPST) Expected to Announce Quarterly Earnings on Tuesday - Defense World

Mar 11, 2025
pulisher
Mar 07, 2025

Tempest Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:TPST - Benzinga

Mar 07, 2025
pulisher
Mar 01, 2025

Comparing Tempest Therapeutics (NASDAQ:TPST) & Nkarta (NASDAQ:NKTX) - Defense World

Mar 01, 2025
pulisher
Feb 17, 2025

Tempest Therapeutics, Inc. (NASDAQ:TPST) Sees Significant Decrease in Short Interest - Defense World

Feb 17, 2025
pulisher
Feb 11, 2025

TPST stock rated a Sector outperform by Scotiabank - Knox Daily

Feb 11, 2025
pulisher
Feb 11, 2025

Tempest gets fast track designation from FDA for amezalpat - MSN

Feb 11, 2025
pulisher
Feb 11, 2025

A closer look at Tempest Therapeutics Inc (TPST)’s stock price trends - US Post News

Feb 11, 2025
pulisher
Feb 11, 2025

Tempest Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation to Amezalpat (TPST-1120) - Marketscreener.com

Feb 11, 2025
pulisher
Feb 10, 2025

Tempest Therapeutics Inc (TPST) Shares Rise Despite Market Challenges - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Tempest Therapeutics Says Amezalpat Receives US FDA Fast Track Status As Treatment for Liver Cancer - Marketscreener.com

Feb 10, 2025
pulisher
Feb 10, 2025

Tempest Granted Fast Track Designation From The U.S. Food And Drug Administration For Amezalpat - Marketscreener.com

Feb 10, 2025
pulisher
Feb 10, 2025

Tempest Granted Fast Track Designation from the U.S. Food - GlobeNewswire

Feb 10, 2025
pulisher
Feb 10, 2025

Tempest's Liver Cancer Breakthrough: FDA Fast-Tracks Drug Showing 6-Month Survival Gain - Stock Titan

Feb 10, 2025
pulisher
Feb 07, 2025

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 07, 2025
pulisher
Feb 07, 2025

Tempest Therapeutics Awards Strategic Compensation Package: Inside the 4-Year Vesting Deal - StockTitan

Feb 07, 2025
pulisher
Feb 04, 2025

Analyzing Ratios: Tempest Therapeutics Inc (TPST)’s Financial Story Unveiled - The Dwinnex

Feb 04, 2025
pulisher
Feb 04, 2025

A stock that deserves closer examination: Tempest Therapeutics Inc (TPST) - US Post News

Feb 04, 2025
pulisher
Jan 27, 2025

Tempest Therapeutics Inc (NASDAQ: TPST) – An Analysis Is What You Need - Stocks Register

Jan 27, 2025
pulisher
Jan 14, 2025

Tempest Therapeutics, Inc. (NASDAQ:TPST) Shares Acquired by Geode Capital Management LLC - Defense World

Jan 14, 2025
pulisher
Jan 06, 2025

Tempest Receives Orphan Drug Designation from the U.S. Food - GlobeNewswire

Jan 06, 2025
pulisher
Jan 06, 2025

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC) - GlobeNewswire Inc.

Jan 06, 2025
pulisher
Jan 02, 2025

Before You Sell Tempest Therapeutics Inc (NASDAQ: TPST) Shares, Here’sWhat You Need To Know. - Stocks Register

Jan 02, 2025
pulisher
Dec 30, 2024

Tempest Therapeutics Inc (NASDAQ: TPST) Investors Should Be Worried About This. - Stocks Register

Dec 30, 2024
pulisher
Dec 14, 2024

TPST Stock Touches 52-Week Low at $0.8 Amid Market Challenges - Investing.com Canada

Dec 14, 2024
pulisher
Dec 13, 2024

TPST Stock Touches 52-Week Low at $0.8 Amid Market Challenges By Investing.com - Investing.com South Africa

Dec 13, 2024
pulisher
Dec 10, 2024

Thinking about buying stock in Nikola, Delcath Systems, Taysha G - GuruFocus.com

Dec 10, 2024
pulisher
Dec 06, 2024

Tempest Therapeutics amends rights agreement By Investing.com - Investing.com Australia

Dec 06, 2024
pulisher
Dec 06, 2024

Tempest Therapeutics amends rights agreement - Investing.com India

Dec 06, 2024
pulisher
Dec 06, 2024

Tempest Therapeutics Awards Key Employee Stock Options in Strategic Compensation Move | TPST Stock News - StockTitan

Dec 06, 2024
pulisher
Nov 27, 2024

Favourable Signals For Tempest Therapeutics: Numerous Insiders Acquired Stock - Yahoo Finance

Nov 27, 2024
pulisher
Nov 25, 2024

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times

Nov 25, 2024

Tempest Therapeutics Inc (TPST) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
大文字化:     |  ボリューム (24 時間):